ARS Pharmaceuticals, Inc (SPRY) - Total Liabilities
Based on the latest financial reports, ARS Pharmaceuticals, Inc (SPRY) has total liabilities worth $213.39 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ARS Pharmaceuticals, Inc cash flow conversion to assess how effectively this company generates cash.
ARS Pharmaceuticals, Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how ARS Pharmaceuticals, Inc's total liabilities have evolved over time, based on quarterly financial data. Check ARS Pharmaceuticals, Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
ARS Pharmaceuticals, Inc Competitors by Total Liabilities
The table below lists competitors of ARS Pharmaceuticals, Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Xinhua Media Co Ltd
SHG:600825
|
China | CN¥1.42 Billion |
|
Shenzhen Absen Optoelectronic Co Ltd
SHE:300389
|
China | CN¥2.64 Billion |
|
Hangzhou Shenhao Technology Co Ltd
SHE:300853
|
China | CN¥1.00 Billion |
|
JM AB (publ)
ST:JM
|
Sweden | Skr15.78 Billion |
|
Eton Pharmaceuticals Inc
NASDAQ:ETON
|
USA | $65.96 Million |
|
Zhejiang Huakang Pharmaceutical Co Ltd
SHG:605077
|
China | CN¥4.32 Billion |
|
M31 Technology Corp
TWO:6643
|
Taiwan | NT$248.51 Million |
|
AnShan Heavy Duty Mining Machinery Co Ltd
SHE:002667
|
China | CN¥2.17 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down ARS Pharmaceuticals, Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ARS Pharmaceuticals, Inc (SPRY) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ARS Pharmaceuticals, Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ARS Pharmaceuticals, Inc (2018–2025)
The table below shows the annual total liabilities of ARS Pharmaceuticals, Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $213.39 Million | +126.16% |
| 2024-12-31 | $94.36 Million | +3786.12% |
| 2023-12-31 | $2.43 Million | -71.60% |
| 2022-12-31 | $8.55 Million | -90.78% |
| 2021-12-31 | $92.72 Million | +129.16% |
| 2020-12-31 | $40.46 Million | +90.40% |
| 2019-12-31 | $21.25 Million | +127.27% |
| 2018-12-31 | $9.35 Million | -- |
About ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is … Read more